The November 2020 issue of Pharmafocus is available to read free online now!

pharmafile | October 27, 2020 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, Biden, Pharmafocus, Trump, UK, US election, brexit, pharma, remdesivir 

The latest monthly edition of Pharmafocus is available to read for free online now!

In exactly one week, the American public will go to the polls to decide whether to endorse current President Donald Trump or challenger Joe Biden to lead the country through the next four years, with the biggest challenge being to face down a pandemic which has claimed over 220,000 lives in the US so far. And with drug pricing and access high on the agenda for voters, there’s a lot at stake for patients and industry alike – you can read our analysis on this issue’s front page.

Across the Atlantic, the UK is facing twin crises as COVID-19 cases spike in spite of evermore stringent local lockdown measures while Brexit negotiations with the EU ramp up the rhetoric and posturing, risking a damaging no-deal in a time when the economy is on its knees.

Richard Torbett, Chief Executive of the Association of the British Pharmaceutical Industry, has warned against such an outcome, saying it is not in the interests of the UK life sciences industry and could lead to up to six weeks of supply delays and cost the country millions. We explore his comments on page 4.

Elsewhere in the issue, we delve into the disappointing news that, according to a large-scale WHO study, remdesivir and three other promising drugs present “little to no” benefit in improving COVID-19 mortality rates. Meanwhile, in our opinion piece, Liz Lynn of the Drug Safety Research Unit presents the organisation’s work in analysing the benefit/risk profile of remdesivir and other repurposed therapies in the treatment of COVID-19.

We also have full-length features on how precision medicine approaches can help the oncology space navigate these difficult times, and on the importance of serialisation in developed and developing nations in fighting the scourge of counterfeit medicines.

Related Content


Long COVID: 15 studies launched with £19.6 million government funding

The UK government has announced the launch of 15 new extensive studies, backed by £19.6 …

Drugmakers fined a record £260 million after 10,000% drug price increase

The UK’s competition authority has issued its largest ever fine of more than £260 million …


New targeted lung cancer treatment coming to UK under MHRA scheme

The MHRA has issued an Early Access to Medicines Scheme (EAMS) positive scientific opinion for …

Latest content